TY - JOUR
T1 - Low-Dose Mitomycin C as a Prophylaxis for Corneal Haze in Myopic Surface Ablation
AU - Thornton, Ivey
AU - Puri, Ashok
AU - Xu, Meng
AU - Krueger, Ronald R.
N1 - Funding Information:
This study was supported by a Cleveland Clinic Institutional Grant from Research to Prevent Blindness, Inc, New York, New York. The authors indicate no financial conflict of interest. Involved in design of study (R.R.K., A.P.); conduct of study and collection of data (A.P.); management and analysis of data (I.T., R.R.K., M.X.); interpretation of data (R.R.K., I.T.); preparation of manuscript (I.T., R.R.K.); and review and approval of manuscript (I.T., A.P., M.X., R.R.K.). The data were collected retrospectively in adherence to the Declaration of Helsinki and all federal or state laws in India.
PY - 2007/11
Y1 - 2007/11
N2 - Purpose: To evaluate the efficacy of low-dose (0.002%) mitomycin C (MMC) vs no prophylactic MMC (control) in reducing corneal haze after surface laser ablation. Design: Two-year retrospective follow-up study performed in Jaipur, India. Methods: Ninety-two eyes with no MMC application and 83 eyes with 0.002% MMC application during laser epithelial keratomileusis (LASEK) were analyzed in a retrospective chart review with one month, two months, three months, six months, one year, and two years of postoperative follow-up. Postoperative haze, visual acuity, and efficacy ratio (EFFR) then were analyzed statistically. Results: The no-dose MMC and low-dose MMC groups were statistically similar except for a thinner corneal pachymetry (P < .001), higher spherical equivalent error (P = .006), and smaller ablation zone (P = .009) in eyes not treated with MMC when subjected to univariate analysis. Multivariate analysis was used to overcome the preoperative statistical differences among the two groups. Eyes treated with low-dose MMC (0.002%) demonstrated statistically less haze at all postoperative time points and in each myopic subgroup (P < .001). The postoperative uncorrected visual acuity (UCVA) and EFFR, however, showed no difference between the groups, except for better EFFR with MMC at one month (P < .001) and two months (P = .034). Conclusions: Low-dose MMC (0.002%) in eyes after LASEK results in less corneal haze than in eyes not receiving this agent. Concerns regarding the potential toxicity of MMC make a 10-fold less concentration more desirable in refractive surgery. Further comparative study of low- vs higher-dose MMC is recommended to characterize its clinical benefit fully.
AB - Purpose: To evaluate the efficacy of low-dose (0.002%) mitomycin C (MMC) vs no prophylactic MMC (control) in reducing corneal haze after surface laser ablation. Design: Two-year retrospective follow-up study performed in Jaipur, India. Methods: Ninety-two eyes with no MMC application and 83 eyes with 0.002% MMC application during laser epithelial keratomileusis (LASEK) were analyzed in a retrospective chart review with one month, two months, three months, six months, one year, and two years of postoperative follow-up. Postoperative haze, visual acuity, and efficacy ratio (EFFR) then were analyzed statistically. Results: The no-dose MMC and low-dose MMC groups were statistically similar except for a thinner corneal pachymetry (P < .001), higher spherical equivalent error (P = .006), and smaller ablation zone (P = .009) in eyes not treated with MMC when subjected to univariate analysis. Multivariate analysis was used to overcome the preoperative statistical differences among the two groups. Eyes treated with low-dose MMC (0.002%) demonstrated statistically less haze at all postoperative time points and in each myopic subgroup (P < .001). The postoperative uncorrected visual acuity (UCVA) and EFFR, however, showed no difference between the groups, except for better EFFR with MMC at one month (P < .001) and two months (P = .034). Conclusions: Low-dose MMC (0.002%) in eyes after LASEK results in less corneal haze than in eyes not receiving this agent. Concerns regarding the potential toxicity of MMC make a 10-fold less concentration more desirable in refractive surgery. Further comparative study of low- vs higher-dose MMC is recommended to characterize its clinical benefit fully.
UR - http://www.scopus.com/inward/record.url?scp=35348952589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35348952589&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2007.07.020
DO - 10.1016/j.ajo.2007.07.020
M3 - Article
C2 - 17889818
AN - SCOPUS:35348952589
SN - 0002-9394
VL - 144
SP - 673-681.e1
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 5
ER -